KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Accumulated Expenses: 2009-2012

Historic Other Accumulated Expenses for Jazz Pharmaceuticals (JAZZ) over the last 1 years, with Sep 2012 value amounting to $13.1 million.

  • Jazz Pharmaceuticals' Other Accumulated Expenses was N/A to $13.1 million in Q3 2012 from the same period last year, while for Sep 2012 it was $13.1 million, marking a year-over-year change of. This contributed to the annual value of $2.2 million for FY2011, which is 109.86% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Other Accumulated Expenses of $13.1 million as of Q3 2012, which was down 30.74% from $18.9 million recorded in Q2 2012.
  • In the past 5 years, Jazz Pharmaceuticals' Other Accumulated Expenses ranged from a high of $18.9 million in Q2 2012 and a low of $1.0 million during Q4 2010.
  • Its 3-year average for Other Accumulated Expenses is $8.7 million, with a median of $8.2 million in 2012.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Other Accumulated Expenses slumped by 40.10% in 2010, and later skyrocketed by 109.86% in 2011.
  • Over the past 4 years, Jazz Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $1.7 million in 2009, then plummeted by 40.10% to $1.0 million in 2010, then skyrocketed by 109.86% to $2.2 million in 2011, then reached $13.1 million in 2012.
  • Its Other Accumulated Expenses stands at $13.1 million for Q3 2012, versus $18.9 million for Q2 2012 and $8.2 million for Q1 2012.